Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRXBiotechnology
-$0.01 today
- Market cap
- $3.85B
- Beta
- 0.74
- P/E (TTM)
- 17.3
- EPS (TTM)
- $1.81
Volume 0.00M
Average 2.17M
CPRX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Catalyst Pharmaceuticals, Inc.NASDAQ: CPRX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $2.66M fell 31.5% year over year, behind the -17.7% change in trailing-twelve-month research & development. Sequentially, it rose 47.3% from the prior quarter. Over 3 fiscal years it compounded at -13.7% a year.
Context
- Research & development amounted to 2.2% of revenue in FY2025, down 0.4 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -31.5% toward the trailing-twelve-month pace of -17.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 12.71M USD
- Year-over-year change
- +0.5%
- 4-year CAGR
- -6.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.71M | +0.5% |
| FY2024 | 2024-12-31 | 12.65M | -86.4% |
| FY2023 | 2023-12-31 | 93.15M | +370.7% |
| FY2022 | 2022-12-31 | 19.79M | +16.8% |
| FY2021 | 2021-12-31 | 16.94M | — |
Research & Development vs competitors
How CPRX compares with its peers on the latest reported figures
- CPRX's LTM Mar 2026 research & development of $11.48M is the lowest of the 9 companies compared; the peer median is $320.57M.
- Its year-over-year change of -17.7% is the lowest of 9, against a peer median of +4.2%.
- Research & development amounts to 1.9% of revenue for CPRX, versus a peer median of 261.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $408.66M | +3.1% | +9.5% | 261.9% | |
| LTM Jun 2026 | $381.91M | -11.4% | +39.8% | 696.2% | |
| LTM Mar 2026 | $342.68M | +13.3% | +6.1% | 518.8% | |
| LTM Mar 2026 | $339.54M | +5.2% | +52.0% | 150.7% | |
| LTM Jun 2026 | $301.59M | +72.6% | +71.3% | — | |
| LTM Sep 2026 | $211.05M | -0.0% | +18.8% | 37026.5% | |
| LTM Jun 2026 | $127.15M | +28.1% | +13.9% | 15.1% | |
| LTM Jun 2026 | $88.21M | -7.8% | -12.9% | 28.6% | |
| LTM Mar 2026 | $11.48M | -17.7% | -13.7% | 1.9% | |
| Peer median (excluding CPRX) | $320.57M | +4.2% | +16.3% | 261.9% | |
Competitors are the stored peer set for CPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 140.83M | 214.2M | 398.2M | 491.73M | 588.99M |
| Cost of Revenue | 21.88M | 34.39M | 51.97M | 68.85M | 87.25M |
| Gross Profit | 118.95M | 179.81M | 346.24M | 422.89M | 501.74M |
| Gross Margin | 84.5% | 83.9% | 86.9% | 86.0% | 85.2% |
| Research & Development | 16.94M | 19.79M | 93.15M | 12.65M | 12.71M |
| Selling, General & Admin | 49.63M | 57.09M | 133.71M | 177.74M | 193.75M |
| Operating Expenses | 66.56M | 77.97M | 259.43M | 227.77M | 243.96M |
| Depreciation & Amortization | 192K | 1.24M | 32.88M | 37.77M | 37.87M |
| EBITDA | 52.86M | 105.96M | 127.39M | 254.04M | 321.39M |
| EBITDA Margin | 37.5% | 49.5% | 32.0% | 51.7% | 54.6% |
| Operating Income | 52.39M | 101.84M | 86.81M | 195.12M | 257.78M |
| Operating Margin | 37.2% | 47.5% | 21.8% | 39.7% | 43.8% |
| Interest Income | 0 | 0 | 0 | 16.06M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 282K | 2.88M | 7.7M | 21.14M | 25.74M |
| Income Before Tax | 52.67M | 104.72M | 94.51M | 216.26M | 283.52M |
| Pre-Tax Margin | 37.4% | 48.9% | 23.7% | 44.0% | 48.1% |
| Income Tax Expense | 13.19M | 21.64M | 23.1M | 52.37M | 69.19M |
| Net Income | 39.48M | 83.08M | 71.41M | 163.89M | 214.33M |
| Net Margin | 28.0% | 38.8% | 17.9% | 33.3% | 36.4% |
| EPS (Basic) | 0.38 | 0.80 | 0.67 | 1.38 | 1.75 |
| EPS (Diluted) | 0.37 | 0.75 | 0.63 | 1.31 | 1.68 |
| Weighted Avg Shares | 103.38M | 103.37M | 106.28M | 118.46M | 122.29M |
| Weighted Avg Shares (Diluted) | 107.8M | 111.38M | 113.75M | 124.94M | 127.26M |
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
Intrinsic Alpha fair value
Locked
Current Price
$31.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.